(19)
(11) EP 3 571 508 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.05.2023 Bulletin 2023/21

(45) Mention of the grant of the patent:
19.04.2023 Bulletin 2023/16

(21) Application number: 18741940.3

(22) Date of filing: 18.01.2018
(51) International Patent Classification (IPC): 
G01N 33/574(2006.01)
C12Q 1/02(2006.01)
C07K 16/28(2006.01)
 A61K 49/00(2006.01)
C07K 16/00(2006.01)
C40B 30/04(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/28; G01N 33/56966; G01N 33/57469; G01N 2400/02; C07K 16/18; C07K 16/34; C07K 16/44
(86) International application number:
PCT/US2018/014260
(87) International publication number:
WO 2018/136649 (26.07.2018 Gazette 2018/30)

(54)

DETECTING CANCER STEM CELLS USING A GLYCAN BIOMARKER

NACHWEIS VON KREBSSTAMMZELLEN UNTER VERWENDUNG EINES GLYCAN-BIOMARKERS

DÉTECTION DE CELLULES SOUCHES CANCÉREUSES À L'AIDE D'UN BIOMARQUEUR À BASE DE GLYCANE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 18.01.2017 US 201762447654 P

(43) Date of publication of application:
27.11.2019 Bulletin 2019/48

(73) Proprietor: SRI International
Menlo Park, CA 94025-3493 (US)

(72) Inventor:
  • WANG, Denong
    Palo Alto CA 94303 (US)

(74) Representative: D Young & Co LLP 
120 Holborn
London EC1N 2DY
London EC1N 2DY (GB)


(56) References cited: : 
WO-A1-2016/201240
 US-A1- 2008 118 432
   
  • HUABEI GUO ET AL: "O -Linked N -Acetylglucosamine ( O -GlcNAc) Expression Levels Epigenetically Regulate Colon Cancer Tumorigenesis by Affecting the Cancer Stem Cell Compartment via Modulating Expression of Transcriptional Factor MYBL1", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 292, no. 10, 17 January 2017 (2017-01-17), pages 4123-4137, XP055740289, US ISSN: 0021-9258, DOI: 10.1074/jbc.M116.763201
  • DENONG WANG ET AL: "Carbohydrate Microarrays Identify Blood Group Precursor Cryptic Epitopes as Potential Immunological Targets of Breast Cancer", JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2015, 1 January 2015 (2015-01-01), pages 1-9, XP055740351, US ISSN: 2314-8861, DOI: 10.1155/2015/510810
  • WANG DENONG ET AL: "Chapter 15: Glycan Markers as Potential Immunological Targets in Circulating Tumor Cells", RETINAL DEGENERATIVE DISEASES: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRINGER, US, PAGE(S) 275 - 284 , 1 January 2017 (2017-01-01), XP009523492, ISBN: 978-3-319-55947-6 Retrieved from the Internet: URL:http://link.springer.com/10.1007/978-3 -319-55947-6_15 [retrieved on 2017-05-31]
  • MARIA TOLOUDI ET AL: "Correlation between Cancer Stem Cells and Circulating Tumor Cells and Their Value", CASE REPORTS IN ONCOLOGY, vol. 4, no. 1, 29 January 2011 (2011-01-29), pages 44-54, XP055390490, DOI: 10.1159/000324403
  • WANG ET AL.: 'Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells' ARCH MED RES vol. 46, no. 8, November 2015, pages 642 - 650, XP029394167
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).